SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Cantor Fitzgerald Reiterates Overweight on Arrowhead Pharmaceuticals, Lowers Price Target to $58

Cantor Fitzgerald reiterates Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Overweight and lowers the price target from $60 to $58.

Benzinga · 05/08/2020 11:02

Cantor Fitzgerald reiterates Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Overweight and lowers the price target from $60 to $58.